Tuesday, September 10, 2013


Experienced Angel Investors Back Technology Providing Better Nicotine Delivery

SALT LAKE CITY, UT (September 9, 2013) – e-Nicotine Technology (eNT) announced today that it has closed a series A-round in excess of $3.8MM, a substantially oversubscribed round for the company. This investment will help to accelerate the development and commercialization of its novel clean electronic nicotine delivery device. “eNT has everything that we were looking for as investors – a great and experienced management team, a novel and proprietary technology, and a huge market with a staggering unmet need. I couldn’t think of a better way to invest than in the health of the human race”, said Don Watkins, Chairman of the Board of Directors.

eNT has already succeeded in creating a clean nicotine aerosol of ideally sized particles for deep lung delivery and rapid absorption. They are now poised to become a leader in the nicotine aerosol industry, which is protected to reach a staggering $1.7B in revenues in the United States this year alone. This financing will be used to gather clinical data on the eNT inhaler, as well as expand the company’s engineering efforts and intellectual property portfolio. Significant investors in the financing included Don Watkins (co-Founder of Handstands), Fraser Bullock (Managing Director at Sorenson Capital) and Christopher B. Munday (Golden Gate Capital), Life Science Angels (Palo Alto, CA) and North Texas Angel Network (Dallas, TX)

"This is a tremendo
us vote of confidence in this team and our technology. By leveraging our expertise in creating condensation aerosols for deep lung delivery and rapid absorption, we are now ready to quickly accelerate the development of our nicotine inhaler”, said Jeff Williams, President and CEO.

“The eNT opportunity nicely fits within LSA’s focus on identifying high impact healthcare opportunities with a clear and efficient path to commercialization. This was an ideal investment for us because of the combination of the team’s expertise and experience in the area, the robust technology and IP, and the need for an improved method to switch from combustible tobacco products to clean nicotine aerosols.  I am excited to also be joining the Board of Directors and contribute to the strategic growth of the company”, said Rich Brenner/LSA.

About e-Nicotine Technology
eNT is a company committed to reducing the harm associated with tobacco products by combining clean nicotine aerosols for inhalation with empowering e-health tools. eNT is developing an electronic nicotine delivery device that produces a condensation aerosol of nicotine using its proprietary thermal drug delivery technology. The eNT platform delivers the right dose of nicotine using the right sized aerosol particles for deep lung delivery.
Joining Jeff Williams (President and CEO) and Michael Hufford, Ph.D. (Chief Medical Officer) on the Board of Directors will be Fraser Bullock, Christopher Munday, Rich Brenner and Don Watkins as Chairman.

For more information on eNT, its products, and other inquiries, please contact: Jeff Williams at +1.925.876.2765 or jwilliams@enicotinetechnology.com, www.enicotinetechnology.com

No comments:

Post a Comment